Dual-action therapies are gaining traction as a groundbreaking approach in the fight against simultaneously HIV and cancer. These treatments target various pathways within cancer cells, offering {a{ promise of improved efficacy and reduced side effects compared to traditional monotherapy approaches. By integrating different therapeutic modalities,